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Abstract 
Introduction:  
Thrombotic thrombocytopenic purpura (TTP) in pregnancy is rare and can be fatal if 
misdiagnosed.  Typically patients present with microangiopathic hemolytic anemia, 
thrombocytopenia, altered mental status, fever, and renal abnormalities 
 
Case Description: 
We are presenting a case of 26 year old pregnant female presented with elevated BP. She had 
scattered Bruises in her legs, thighs and arms along with +2 bilateral pitting leg edema. Initial 
and subsequent laboratory studies showed features of microangiopathic hemolytic anemia 
(MAHA), which brought up the suspicion of HELLP (hemolysis, elevated liver enzymes, low 
platelets) syndrome initially. Labor was induced after transfusion of 2 units of PRBCs and 2 
units of Platelets. The patient platelets and hemoglobin showed no improvement after delivery 
and she continued to have hemolysis despite delivery and steroids administration. Daily 
therapeutic plasma exchange was initiated as the index of suspicion for TTP increased. After two 
sessions, there was a significant improvement in the platelet count and hemolysis profile which 
were normalized by the 4th session. 
 
Conclusion: 
Congenital TTP is a rare syndrome that clinicians should be aware of. Early initiation of plasma 
exchange dramatically improves survival from less than 10% to approximately 80%. This can 
only be achieved by having high level of suspicion and awareness to this possibility. 
 
 
Keywords:  TTP, Congenital TTP, Pregnancy, HELLP, Preeclampsia, Upshaw-Schulman 
syndrome 
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 Introduction 
 
Thrombotic thrombocytopenic purpura (TTP) in pregnancy is rare and can be fatal if 
misdiagnosed.1  Hereditary or acquired TTP must be considered in the differential diagnosis of 
pregnancy-induced microangiopathic hemolytic anemia (MAHA) along with severe 
preeclampsia as in hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome.2  In 
TTP, early initiation of plasma exchange dramatically improves survival from less than 10% to 
approximately 80%.1  
Case Presentation 
 
A 26 year old Caucasian female presented for a routine peripartum visit. She was G1P0 at 35 
weeks gestation. Her pre-partum history was significant for mild bruising tendency since 
childhood and subnephrotic proteinuria.   
She was found to have elevated blood pressure of 140/90 and had 13 lbs. weight gain over a two 
week period. She reported increasing swelling in her legs and face one week prior to 
presentation. She denied headaches, blurry vision, right upper quadrant pain, dyspnea, nausea, or 
vomiting. Other than hypertension, physical exam showed vital signs of HR 88 RR 18 and Temp 
of 98.  Abdomen was soft, gravid, and non-tender. She had scattered bruises in her legs, thighs 
and arms along with +2 bilateral pitting leg edema. Initial and subsequent laboratory studies are 
shown in the table. 
The combination of high blood pressure, proteinuria, hemolytic anemia and thrombocytopenia 
brought up the suspicion of HELLP syndrome.  Labor was induced after transfusion of 2 units of 
PRBCs and 2 units of platelets.  The mother and her newborn were closely observed on labor and 
delivery unit.  The fetal heart rate showed no major abnormalities. Apgar score was 3 & 8 at 1 & 
5 minutes respectively.  The patient platelets and hemoglobin showed no improvement and she 
continued to have hemolysis despite delivery and steroids administration.  At this point, daily 
therapeutic plasma exchange was initiated as the index of suspicion for TTP increased.  After 
two sessions, there was a significant improvement in the platelet count and hemolysis profile 
which were normalized by the 4th session. 
Discussion 
 
TTP (Moschcowitz syndrome) is an acute, rare, and potentially fatal disorder.3  The classical  
pentad of clinical features includes microangiopathic hemolytic anemia, thrombocytopenia, 
neurologic symptoms, fever, and renal abnormalities.4   It is caused by absent or severely 
depleted ADAMTS-13, the von Willebrand factor (VWF) cleaving protease.3   It is either 
acquired, likely immune mediated, or hereditary, also called Upshaw-Schulman syndrome.5  
Upshaw-Schulman syndrome or Congenital TTP (cTTP) is caused by homozygous or compound 
heterozygous ADAMTS13 mutations.6-7   It is diagnosed by the documentation of a severe 
deficiency in ADAMTS13 activity (<10%), and absence of ADAMTS13 autoantibody.  The 
diagnosis is confirmed by documentation of ADAMTS13 mutation.8  cTTP clinical signs may be 
mild or absent during childhood.  History of easy bruising during childhood due to isolated 
thrombocytopenia can be the only symptom.9  There are two age clusters for the initial episode 
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of cTTP; about half of patients have their first acute episode in infancy or early childhood, while 
the other half remain asymptomatic until adulthood,9  with pregnancy being the most important 
precipitant of initial acute episode.7   Physiologic changes during pregnancy including 
progressive increase of VWF and associated decrease of ADAMTS13 can be considered a likely 
triggering mechanism for the acute episodes of TTP.5  Pregnancy induced cTTP mostly occurs in 
the third trimester,3,9  which is likely related to the period over which the level of VWF is 
increased during pregnancy.5,9   
On the other hand, preeclampsia/HELLP syndrome can be associated with thrombocytopenia, 
microangiopathic hemolytic anemia, neurologic symptoms, and renal insufficiency, making their 
distinction from TTP difficult or impossible especially since their onset can be delayed to the 
third trimester of pregnancy as in TTP.3,9   There are some features that may favor the diagnosis 
of TTP over HELLP syndrome which include severe thrombocytopenia (less the 20,000) and an 
elevated LDH-to-AST ratio.3  ADAMTS-13 activity might be reduced along with elevated VWF 
levels in HELLP syndrome, but a severe reduction in ADAMTS-13 activity (<10%)10  along 
with an increase in ultra large VWF multimers is usually suggestive of TTP.3  On the other hand 
HELLP syndrome is usually associated with preeclampsia, so hypertension and proteinuria 
would favor a diagnosis of HELLP syndrome.  
The probability of serious maternal and fetal complications during pregnancy is high in patients 
with cTTP.5  Untreated TTP is associated with a > 90% mortality.1   Without appropriate 
treatment, the risk of recurrent episode in patients with cTTP during the next pregnancy is almost 
100%.5   Daily plasma exchange and glucocorticoids is the main therapy for adult patients with 
TTP during pregnancy,4  which dramatically improved survival from less than 10% to 
approximately 80%.1,3   Patients with cTTP respond quickly to plasma transfusion either upon 
need or intermittently every 2-3 weeks as a prophylactic therapy. Some plasma derived factor 
VIII/VWF concentrates contain sufficient amount of ADAMTS13 that was found to be useful in 
treating cTTP, replacing FFP and plasma exchange.11  
Conclusion  
 
Congenital TTP is a rare syndrome that clinicians should be aware of. It can be misdiagnosed in 
pregnancy as HELLP syndrome, which is more common in this group of patients. If untreated, 
death from disseminated microvascular thrombosis occurs which makes early detection and 
treatment of this disease life saving. This can only be achieved by having high level of suspicion 
and awareness to this possibility. 
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Table: The patient laboratory work up 
Test Result Reference Range 
Hemoglobin 7.2 g/dl 12.0-16.0 
Platelets 16 15-440 
WBC 9.2 4.5-10.0 
Sodium 141 135-145 
Potassium 4.1 3.5-5.0 
Calcium 8.2 8.5-10.5 
Creatinine 0.78 0.6-1.10 
Blood Urea Nitrogen 16 7-21 
Glucose 95 65-110 
Albumin 3.2 3.5-5.0 
Total Bilirubin 0.6 0.3-1.30 
AST 31 10-40 
ALT 21 7-40 
GGT 9 12-58 
PT 9.9 9.4-12.4 
aPTT 25.5 20.41-33.39 
INR 0.92 0.90-1.30 
Urine Creatinine 265 20-320 
Urine Protein 870 40-80 
Urinalysis Moderate amount of intact RBC 0-1 RBC 
Urine drug screen negative Negative 
ANA negative Negative ( < 1:80) 
HIV negative Negative 
Hepatitis Panel negative Negative 
Blood group O+  
Peripheral Blood Smear Schistocytes, Microspherocytes 
and Toxic PMNs 
 
Direct Coombs Test negative Negative 
Reticulocyte Count 9.88 0.73-3.12 
Haptoglobin Less than 7 32-154 
Fibrinogen 493.5 140.0-498.0 
LDH 473 100-190 
Uric Acid 7.1 2.5-7.5 
Anticardiolipin Negative (<9) Negative (0-14) 
B2 Glycoprotein 1 Antibodies Negative (<9) Negative (0-20) 
ADAMTS13 Activity Less than 10% >66% 
ADAMTS13 Antibody Negative (<9) Negative (<12) 
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Placenta Pathology 
Intraparenchymal infarct, 
Perivillous and Perivascular 
fibrin deposition 
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